Trial Profile

A Phase I/II Study of Indoximod in Combination With Gemcitabine and Nab-Paclitaxel in Patients With Metastatic Adenocarcinoma of the Pancreas

Status: Completed

Phase of Trial: Phase I/II

Latest Information Update: 07 Aug 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Gemcitabine (Primary) ; Indoximod (Primary) ; Paclitaxel (Primary)
Indications Adenocarcinoma; Pancreatic cancer; Pancreatic ductal carcinoma
Focus Adverse reactions; Therapeutic Use
Sponsors NewLink Genetics Corporation

Most Recent Events

03 Aug 2023 Results examining tissue-based correlates of treatment response and resistance using matched baseline and on-treatment biopsies collected from patients with PDA treated in the first-line metastatic setting, published in the Clinical Cancer Research
21 Feb 2019 Status changed from active, no longer recruiting to completed.
09 Nov 2018 Results presented in the NewLink Genetics Corporation media release.

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com